# Phase I/Ib Study of NK Expressing an Affinity-enhanced T-cell Receptor (TCR) Against the NY-ESO-1

> **NCT06083883** · PHASE1 · RECRUITING · sponsor: **M.D. Anderson Cancer Center** · enrollment: 44 (estimated)

## Conditions studied

- Synovial Sarcoma
- Myxoid/Round Cell Liposarcoma

## Interventions

- **DRUG:** Fludarabine phosphate
- **DRUG:** NY-ESO-1 TCR/IL-15 NK
- **DRUG:** Cyclophosphamide

## Key facts

- **NCT ID:** NCT06083883
- **Lead sponsor:** M.D. Anderson Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-03-27
- **Primary completion:** 2026-11-30
- **Final completion:** 2028-11-30
- **Target enrollment:** 44 (ESTIMATED)
- **Last updated:** 2026-04-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06083883

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06083883, "Phase I/Ib Study of NK Expressing an Affinity-enhanced T-cell Receptor (TCR) Against the NY-ESO-1". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT06083883. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*